XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 37,759,327 $ 17,164,177
Investment in debt securities - available for sale, at fair value 15,000,045
Receivable on sale of net operating losses 1,845,823
Advances and deposits on clinical programs and other current assets 1,643,195 1,660,695
Total current assets 56,248,390 18,824,872
Property and equipment (at cost, less accumulated depreciation and amortization) 389,648 294,551
Other assets:    
Deferred income tax asset 1,845,823
In-process research and development, net 13,366,234 13,366,234
Goodwill 1,976,101 1,976,101
Operating lease right-of-use assets, net 945,070 1,047,336
Other intangible assets, net 56,831 113,660
Deposits and other assets 58,761 58,761
Total other assets 16,402,997 18,407,915
Total assets 73,041,035 37,527,338
Current liabilities:    
Accounts payable - trade 2,104,864 2,244,847
Other accrued liabilities 1,803,469 2,458,532
Notes payable - current portion, net of deferred financing costs 1,836,436 1,116,663
Operating lease liability - current portion 445,560 433,413
Deferred revenue - current portion 500,000 500,000
Total current liabilities 6,690,329 6,753,455
Earn-out milestone liability 7,169,000 7,018,000
Notes payable - non-current portion, net of deferred financing costs 3,252,025 3,934,497
Operating lease liability - non-current portion 594,623 710,305
Deferred revenue - non-current portion 375,000 500,000
Total liabilities 18,080,977 18,916,257
Commitments and contingencies
Stockholders' equity:    
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at March 31, 2021 and December 31, 2020)
Common stock - $0.01 par value (112,500,000 shares authorized; 75,019,608 and 40,701,356 shares issued at March 31, 2021 and December 31, 2020, respectively, and 75,019,274 and 40,701,022 shares outstanding at March 31, 2021 and December 31, 2020, respectively) 750,196 407,014
Additional paid-in capital 371,982,609 330,289,596
Accumulated other comprehensive gain 1,785
Accumulated deficit (317,689,344) (312,000,341)
Total stockholders' equity before treasury stock 55,045,246 18,696,269
Treasury stock, at cost (334 shares at March 31, 2021 and December 31, 2020) (85,188) (85,188)
Total stockholders' equity 54,960,058 18,611,081
Total liabilities and stockholders' equity $ 73,041,035 $ 37,527,338